Basic Prochlorperazine Information

• INN (International Nonproprietary Name): Prochlorperazine.
• Brand Names Available In Canada (English): Compazine and various generics; brand packaging historically includes tablets (5 mg, 10 mg), suppositories, injectable vials and syrup.
• ATC Code: N05AB04.
• Forms & Dosages: Tablets 5 mg and 10 mg (rare 25 mg); suppositories 25 mg; injectable ampoules/vials 5 mg/mL and 12.5 mg/mL for IM/IV; oral solution/syrup 5 mg/5 mL.
• Manufacturers In Canada (English): Heritage Pharmaceuticals, Teva, Sandoz, Fresenius Kabi, Medochemie and other generic suppliers (as listed by product manufacturers and suppliers).
• Registration Status In Canada (English): Not specified.
• OTC / Rx Classification: Prescription Only (Rx) in major jurisdictions.
• Standard Adult Doses By Indication: Severe nausea/vomiting 5–10 mg orally three to four times daily or 5–10 mg IM/IV once or twice daily; psychosis initial dosing 5–10 mg three to four times daily with specialist titration.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Worried about how recent evidence affects safety and use?

Systematic reviews and pharmacovigilance summaries from 2022 to 2024 reconfirm prochlorperazine’s role as an effective, low-cost antiemetic for acute severe nausea and vomiting.

Canadian hospital audits from 2022–2023 describe frequent inpatient IV and IM use for refractory emesis and short outpatient tablet courses for community treatment.

Global comparative reviews through 2024 show ondansetron and metoclopramide often preferred for specific settings such as chemotherapy-induced or postoperative nausea.

Those reviews nevertheless note that prochlorperazine remains commonly used where cost or availability limits access to higher-cost alternatives.

Main Outcomes

Patients treated acutely for severe nausea often achieve rapid symptom relief with injectable prochlorperazine in emergency and inpatient settings.

Outpatient prescriptions are typically short courses under seven days, consistent with product monographs and clinical practice.

Comparative effectiveness places ondansetron ahead for chemo and post-op nausea, while prochlorperazine performs well for general acute emesis in low-resource settings.

Safety Observations

Post-market data emphasize dose-related extrapyramidal symptoms and anticholinergic effects as the most frequently reported adverse reactions.

Canadian adverse drug reaction reports over 2022–2024 note higher EPS reporting in younger adults and increased sedation-related falls among older adults.

Observational work in 2023–2024 raised caution about antipsychotic use in dementia-related psychosis, aligning with Health Canada and international advisories to avoid long-term use in that population.

Clinical Mechanism Of Action

Layman’s Explanation

Are you wondering how prochlorperazine actually stops severe nausea?

Prochlorperazine blocks dopamine receptors in the brain areas that trigger nausea and vomiting, so it reduces the feeling and reflex of vomiting.

The drug’s sedating effects come partly from the same brain activity and from additional mild antihistaminic and anticholinergic action.

Scientific Breakdown

Prochlorperazine belongs to the piperazine-phenothiazine class and acts primarily as a dopamine D2 receptor antagonist, according to mechanistic reviews through 2024.

At therapeutic doses it crosses the blood–brain barrier to inhibit D2 receptors in the chemoreceptor trigger zone (area postrema), which mediates antiemetic activity.

Central D2 antagonism in mesolimbic pathways underpins its antipsychotic effects when used under specialist supervision.

Receptor Profile

Primary action is D2 receptor antagonism.

Moderate antihistaminic and anticholinergic binding contributes to sedation and antimuscarinic side effects.

Pharmacokinetics

Oral bioavailability is moderate and variable between individuals.

Hepatic metabolism yields metabolites excreted renally, and injectable formulations provide rapid onset for acute care.

Clinical monographs emphasize a dose-dependent risk of extrapyramidal symptoms due to central D2 blockade and recommend dose adjustments in hepatic impairment.

Scope Of Approved And Off-Label Use

Health Canada Approvals (DIN-Based)

What is prochlorperazine officially approved to treat in Canada?

Product monographs list prochlorperazine as prescription-only and approved for nausea and vomiting and for psychotic disorders, with tablet, suppository, syrup and injectable forms reflecting international approvals.

Compazine has been marketed historically in Canada, and generics from major suppliers maintain availability in the Canadian market.

Notable Off-Label Trends In Canadian Practice

Clinicians in emergency, palliative and inpatient settings commonly use low-dose IV/IM prochlorperazine for refractory nausea, a pragmatic off-label approach supported by audits.

Palliative care prescribers may favour suppositories or injectables for patients who cannot take oral medication.

Pediatric use is cautious, with older dosing references suggesting approximately 0.13 mg/kg orally every 6–8 hours, but Health Canada cautions on use in very young children and recommends specialist dosing for children under two years or under 10 kg.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ list prochlorperazine variably, often under restricted criteria like palliative care.

Dosage Strategy

General Dosing Per Health Canada Monographs

How much should adults take for nausea or psychosis?

For acute severe nausea the usual adult oral dose is 5–10 mg three to four times daily, with IM or IV dosing at 5–10 mg once or twice daily for inpatient control.

For psychotic disorders initial schedules often start at 5–10 mg three to four times daily with specialist titration; historical maximums approach 150 mg/day but modern practice avoids such high totals because of EPS risk.

Condition-Specific Dosing Adjustments

Pediatric dosing appears in older references as roughly 0.13 mg/kg orally every 6–8 hours, but specialist oversight is required and use in very young children is restricted.

Elderly patients should receive the lowest effective dose and have longer dosing intervals, with specific monitoring for hypotension, sedation and extrapyramidal symptoms.

Hepatic and renal impairment require dose reduction and closer monitoring due to primary hepatic metabolism and renal excretion of metabolites.

Suppositories (25 mg) and injectables (5 mg/mL, 12.5 mg/mL) are typically used singly or for short courses; record route-specific onset and duration in patient notes.

Safety Protocols

Contraindications (Canadian Advisories)

Can anyone take prochlorperazine safely?

Absolute contraindications are known hypersensitivity to prochlorperazine or phenothiazines, comatose states or severe CNS depression, and children under two years or under 10 kg for oral use unless approved by a specialist.

Patients with bone marrow suppression are also contraindicated.

Adverse Effects (Post-Market Reports)

Common adverse reactions include drowsiness, blurred vision, dry mouth, constipation, orthostatic hypotension and photosensitivity.

Extrapyramidal symptoms such as acute dystonia, parkinsonism and akathisia are frequently reported and are dose-dependent.

Serious but rare events include neuroleptic malignant syndrome and tardive dyskinesia after prolonged exposure, supporting warnings against long-term use in dementia-related psychosis.

Protocols for safe use emphasise a baseline assessment including cardiac history and QT risk, fall-risk documentation in seniors, and rapid EPS management with anticholinergic antiparkinson agents or drug discontinuation as clinically indicated.

Health Canada’s Canada Vigilance Program is the channel for reporting suspected adverse drug reactions.

Interaction Mapping

Food Interactions Common In Canadian Diet

Is it safe to drink or eat normally while taking prochlorperazine?

Alcohol increases CNS depression, sedation and orthostatic hypotension when taken with prochlorperazine and should be avoided.

No routine food interactions are outlined beyond potentiation of sedative effects with heavy alcohol intake.

Drug Combinations Flagged By Health Canada

Key drug interactions include additive extrapyramidal risk when combined with other antipsychotics or metoclopramide.

CNS depressants such as opioids, benzodiazepines and sedating antihistamines increase sedation and respiratory depression risk when co-prescribed.

QT And Cardiac Interactions

Caution is advised with other QT-prolonging agents such as some antiarrhythmics and macrolide antibiotics and in the setting of electrolyte disturbances; ECG monitoring is reasonable in high-risk patients.

Metabolic Interactions

Because of hepatic metabolism, review concomitant CYP inhibitors or inducers such as certain antivirals and antifungals before initiating therapy.

Community pharmacy dispensing software in major Canadian chains will usually flag these interactions at point of sale.

Patient Experience Analysis

Canadian Survey Data

What do patients say about taking prochlorperazine?

Clinic surveys in Canada from 2021–2024 and community pharmacy feedback report high short-term satisfaction for nausea control but frequent complaints about sedation, dry mouth and extrapyramidal symptoms.

Prescriptions filled in community pharmacies are usually for short tablet courses, while suppository and injectable forms are most common in hospital and palliative settings.

Forum And Community Pharmacy Trends

Online forums and patient groups discuss affordability and accessibility, noting that generic availability helps stabilise supply but provincial formulary differences can affect out-of-pocket costs.

Pharmacy counselling in Canada commonly focuses on fall-risk counselling for seniors and EPS warning signs for younger adults, plus advice to avoid alcohol.

Demand for alternatives such as ondansetron arises because of tolerability advantages for some patients, but cost and formulary limits keep prochlorperazine in regular use.

Distribution And Pricing Landscape

National Pharmacy Chains

How easy is it to find prochlorperazine in Canada?

Major chains including Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs routinely stock oral tablets and sometimes suppositories for community dispensing.

Injectable forms are typically hospital supply and are dispensed by institutional pharmacies.

Online Pharmacy Availability & Provincial Restrictions

Online Canadian pharmacies sell prescription-only products with a valid prescription and follow provincial rules for mail-order dispensing.

Some provinces place restrictions on mailing certain formulations such as injectables, and provincial formularies list prochlorperazine under varying criteria which affects coverage.

In our online pharmacy, prochlorperazine is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

For cash-pay patients US generic pricing can sometimes be lower, but Canadian DIN regulation, bilingual labelling and provincial drug coverage often offset marginal price differences.

Drug shortages and supplier consolidation between 2022 and 2024 have occasionally affected availability, prompting pharmacists to suggest therapeutic alternatives when stockouts occur.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

Which options are considered instead of prochlorperazine?

Relevant alternatives with Canadian DINs include ondansetron (5-HT3 antagonist), metoclopramide (prokinetic with antiemetic action), promethazine (phenothiazine antihistamine) and haloperidol for certain off-label uses.

Pros And Cons Checklist

• Ondansetron: Better tolerability in many chemo/post-op settings, but higher cost than prochlorperazine.
• Metoclopramide: Useful for gastroparesis due to prokinetic action; EPS risk increases at higher doses.
• Promethazine: Effective antiemetic with sedating and anticholinergic effects similar to phenothiazines.
• Haloperidol: Sometimes used for severe emesis or agitation; requires specialist oversight and carries antipsychotic risk profile.

Choice of alternative depends on indication, comorbidities, tolerability priorities and provincial formulary coverage.

Regulatory Status

Health Canada Approval Process

How is prochlorperazine regulated in Canada?

Products require Health Canada Notice of Compliance and an assigned Drug Identification Number (DIN) for marketing and reimbursement tracking.

Regulatory oversight includes product monograph approval, post-market vigilance and periodic labelling updates when safety signals emerge.

DIN And Bilingual Labelling Rules

Canadian rules require bilingual labelling (English and French) for products distributed nationally, and provincial procurement uses DINs to track coverage and reimbursement.

Manufacturers must notify Health Canada of shortages, and provincial drug plans may list specific DINs for reimbursement; pharmacists must verify DIN, expiry and bilingual information at dispensing.

Consolidated FAQ

Is prochlorperazine safe for seniors?

It can be used in older adults but start at the lowest effective dose and monitor for sedation, hypotension and extrapyramidal symptoms; avoid long-term use in dementia-related psychosis as advised by regulatory bodies.

Is prochlorperazine covered by provincial drug plans?

Coverage varies by province and indication; Ontario Drug Benefit, BC PharmaCare and RAMQ list it under restricted criteria such as palliative care or severe nausea.

Can I take alcohol while on prochlorperazine?

No; alcohol increases sedation and the risk of falls and orthostatic hypotension when combined with prochlorperazine.

What are common side effects?

Drowsiness, dry mouth, blurred vision, constipation and extrapyramidal symptoms such as tremor or dystonia are common; seek urgent care for severe muscle spasms, high fever or confusion which could signal neuroleptic malignant syndrome.

What are alternatives if side effects are intolerable?

Discuss ondansetron, metoclopramide or promethazine with the prescriber; the best option depends on the cause of nausea, drug tolerability and provincial coverage.

Visual Guide

What quick visuals help patients remember dosing and safety?

Suggested infographic panels include a dosing flowchart (oral 5–10 mg TID–QID; IM/IV 5–10 mg once daily; suppository 25 mg single or short course), a provincial coverage snapshot, purchase channels and safety icons highlighting EPS and fall risk.

Graphics should cite Health Canada monographs and include bilingual labels for national use.

Storage And Transport

Canadian Household Guidelines

How should patients store tablets and syrup at home?

Store tablets and syrups at room temperature, ideally between 15 and 30°C, away from excessive moisture and light.

Keep medications in their original packaging with childproof caps and do not store in bathrooms where humidity is high.

Cold-Chain Storage Where Applicable

Injectable vials and ampoules are generally room-temperature stable for prochlorperazine, but follow manufacturer instructions and hospital sterile handling policies.

Community pharmacies must keep DIN and batch records and follow provincial rules for transport, and patients travelling across borders should carry original packaging and prescriptions to satisfy customs and pharmacy requirements.

Dispose of unused medication through provincial pharmacy take-back programmes to reduce environmental contamination.

Guidelines For Proper Use

Advice From Canadian Pharmacists

What practical counselling should a patient expect at the pharmacy?

Pharmacists advise documenting indication, route and expected duration at dispensing, and they counsel about common adverse effects, signs of EPS and fall prevention strategies for seniors.

Patients should be warned to avoid alcohol and other CNS depressants, to report involuntary movements promptly, and to store medication safely.

Provincial Health Authority Guidance

Provincial formularies and prescribing guidance generally favour short courses for nausea and specialist oversight for psychiatric indications.

Many provinces require documented justification for long-term antipsychotic prescribing in older adults, and transitions of care should reconcile injectable versus oral dosing to avoid duplication.

Pharmacists use provincial drug-benefit checks and DIN verification to support patients with coverage and substitution questions.

Consolidated Delivery Across Canada (English)

Concluding Safety Notes

What are the key takeaways for patients and prescribers?

Prochlorperazine is a long-standing, effective, low-cost option for acute severe nausea and for short-term psychiatric use under specialist care.

Safety considerations—primarily dose-related extrapyramidal symptoms, anticholinergic effects and sedation—drive conservative use in elderly patients and avoidance of long-term prescribing in dementia-related psychosis.

Always check provincial formularies for coverage and consult pharmacists about interactions, dosing adjustments for liver or kidney impairment, and monitoring requirements for older adults.

Report suspected adverse reactions to Health Canada’s Canada Vigilance Program if an unexpected or severe event occurs.